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Taxol has been used effectively in cancer therapies. Our 
previous  study  demonstrated  that  taxol  induced  altered 
maturation and improved viability of dendritic cells (DCs). 
However, the effects of taxol on DC viability have not been 
fully  elucidated.  In  the  present  study,  flow  cytometric 
analyses  revealed  that  taxol  treatment  significantly 
increased the number of viable DCs and the expression 
levels  of  a  representative  anti-apoptotic  protein  Bcl-xL. 
Furthermore, mobilization of the p65 subunit of nuclear 
factor-κB (NF-κB) from the cytosol to the nucleus in DCs 
was observed by confocal microscopy. An inhibition assay 
using  N-p-tosyl-L-phenylalanine  chloromethyl  ketone 
confirmed  that  NF-κB  was  intimately  involved  in  the 
effects of taxol on DC viability. In addition, we investigated 
the  mechanisms  of  taxol  enhancement  of  DC  viability. 
Since taxol is a popular anticancer agent used in clinic, 
this study may provide a rationale for the use of taxol in 
DC  immunotherapy  to  treat  cancer  patients.  Taken 
together,  these  results  confirm  that  taxol  increases  DC 
viability, and this information may provide new insights 
for new clinical applications of both taxol and DCs.
Keywords: apoptosis, dendritic cell, NF-κB, taxol, viability
Introduction
  Taxol is a well-known anticancer drug used for many 
types of cancers, including breast, ovarian, and non-small 
cell lung cancers [4,22]. Taxol is purified from Taxus 
brevifolia and acts as a microtubule-targeting anticancer 
drug by hindering the depolymerization of microtubules 
within cancer cells [21]. The effects of taxol on a variety of 
immune cells have been studied extensively. In 
taxol-treated macrophages, the expression levels of 
inducible nitric oxide synthase were elevated and the 
production of interleukin-12 (IL-12), which is a critical 
cytokine in innate and cell-mediated immunity, was 
increased [10,14]. Furthermore, it was suggested that taxol 
might enhance the cytotoxic activity of natural killer cells 
[12]. Dendritic cells (DCs), the specialized antigen- 
presenting cells that prime naïve lymphocytes for host 
immune responses, are a likely target of taxol [1]. 
However, the effects of taxol on DCs have not been fully 
elucidated.
  Many anticancer drugs destroy not only cancer cells, but also 
immune-related cells and bone marrow cells. The destruction 
of these latter cells results in immunosuppression and failure 
of hematopoietic homeostasis [19].  Interestingly, our 
previous study demonstrated that taxol induced the altered 
maturation of DCs by the enhancement of surface 
maturation markers, a low percentage of apoptotic cells, 
and a low proliferation of allogeneic splenocytes [6]. This 
study investigated the mechanism by which taxol induces 
DC survival and demonstrated that taxol sustained DC 
viability by protecting against cytokine withdrawal- 
induced apoptosis.
Materials and Methods
Animal and reagents
  C57BL/6  (H-2K
b) and BALB/c (H-2K
d) mice were 
purchased from Orient BIO (Korea) and maintained in the 
animal facility of our laboratory. Female mice (7∼12 
w e e k  o f  a g e )  w e r e  u s e d  i n  t h i s  s t u d y .  A l l  a n i m a l  
experiments were performed based on the guideline of Jeju 
National University for laboratory animal use and care. 
Taxol (Sigma, USA) purified from Taxus brevifolia was 
dissolved in dimethyl sulfoxide (Sigma, USA).
Generation of DCs
  DCs were cultured as described previously [6]. In brief, 
bone marrow cells were harvested from 7∼12-week-old 
C57BL/6 mice [8] and cultured in 6-well culture plates 
using RPMI 1640 media (Invitrogen, USA) containing 5% 100    Mi-Hyoung Kim et al.
fetal bovine serum (Invitrogen, USA), 2 mM L-glutamine, 
100 U/ml penicillin/streptomycin (Invitrogen, USA) and 
10 ng/ml granulocyte-macrophage colony-stimulating 
factor (GM-CSF; Biosource International, USA). The 
floating cells were used as DCs 6∼10 days after culture. 
DCs generally consisted of ＞ 85% CD11c
+ cells, as 
measured by flow cytometric analysis.
Quantitation of DC viability
  To measure the viability of DCs, we analyzed the DC 
population using cell size-based flow cytometric analysis. 
The population of viable DCs in the dot plot was gated and 
confirmed based on the expression of surface DC markers, 
CD11c and major histocompatibility complex (MHC) 
class II molecules. For this, phycoerythrin-labeled anti- 
CD11c antibody and fluorescein isothiocyanate (FITC)- 
labeled anti-MHC class II antibody were used (all from BD 
Biosciences, USA). Cell viability was confirmed by the 
trypan blue exclusion test and annexin V-FITC/propidium 
iodide (PI) staining (Biosource International, USA).
Measurement of cytokine production
  DCs were treated in 6-well culture plates with medium 
alone or with 1 or 5 μg/ml taxol for 24 or 48 h. The 
supernatants were harvested from the cultures and used for 
the determination of IL-12 and tumor necrosis factor-α 
(TNF-α) production, both of which are important cytokines 
for DC function [2]. Cytokine concentrations were measured 
by using CytoSet antibody pairs (Biosource International, 
USA) by enzyme-linked immunosorbent assay (ELISA) 
according to the manufacturer’s instructions.
Flow cytometric analysis
    DCs were stained for flow cytometric analysis as 
described previously [8]. Annexin V-FITC/PI staining was 
performed according to the manufacturer’s instruction. 
Stained cells were analyzed using FACSCalibur with 
CellQuest software (Beckton Dickinson, USA).
Western blot analysis
  Western blot analysis was performed as described in a 
previous study [7]. In brief, DCs were treated in 6-well 
culture plates with 5 μg/ml taxol for 6, 24 or 48 h. DC 
lysates were harvested and the protein concentrations were 
determined using Bradford protein assay (Bio-Rad, USA). 
Proteins were separated in a 12% polyacrylamide gel and 
blotted onto nitrocellulose membranes. Anti-Bcl-2, anti- 
Bcl-xL, and anti-Bax antibodies (Santa Cruz Biotechnology, 
USA) were used, followed by their respective horseradish 
peroxidase-labeled secondary antibodies (Santa Cruz 
Biotechnology, USA), to detect specific proteins. As an 
internal control, anti-β-actin antibody (Sigma, USA), 
followed by its respective secondary antibody (Santa Cruz 
Biotechnology, USA), was used to detect β-actin. Protein 
bands were visualized using SuperSignal West Pico 
Chemiluminescent Substrate (Pierce Biotechnology, USA).
Confocal  microscopic  analysis  and  inhibitor 
treatment
  DCs were treated on chamber slides with medium alone, 
5 μg/ml taxol for 3 h. In brief, cells were fixed with 2% 
paraformaldehyde-containing phosphate-buffered saline 
and then stained with 4 μg/ml tetramethylrhodamine 
isothiocyanate-labeled anti-nuclear factor-κB (NF-κB) 
p65 monoclonal antibody (Santa Cruz Biotechnology, 
USA). The pictures of stained DCs on chamber slides were 
obtained using a confocal microscope (Olympus Optical, 
Japan). For the NF-κB inhibitor assay, DCs were treated 
with N-p-tosyl-L-phenylalanine chloromethyl ketone 
(TPCK; Sigma, USA).
Statistical analysis
  Data were obtained from more than three experiments. To 
compare the difference between groups, Student’s t-test or 
Tukey-Kramer multiple comparison test was used. A p 
value ＜ 0.05 was determined to be statistically significant.
Results
Taxol increases DC viability
    In the flow cytometric analysis, two different cell 
populations were gated based on cell size; region R1 
included DCs, as confirmed by staining for cell-specific 
surface markers, CD11c and MHC class II, whereas region 
R2 contained contaminating cells, mainly dead cells (Fig. 
1). In preliminary experiments, we confirmed that the 
viable DCs show higher FSC/SSC, which means bigger 
than dead DCs since the cell size of DCs are reduced upon 
cell death. Based on this analysis, the taxol-treated DCs 
(TaxolDCs) showed significantly higher viability than 
medium alone-treated DCs (ContDCs). These results 
suggest that taxol may protect DCs from cytokine- 
withdrawal-induced cell death.
The enhanced cytokine production of DCs treated 
by taxol
  The TaxolDCs treated with 5 μg/ml of taxol produced 
higher amounts of both cytokines than the ContDCs, at 24, 
48 h of incubation time (Fig. 2). However, the taxol 
concentration used was critical for the level of cytokine 
production; 1 μg/ml of taxol induced only marginal 
production of these cytokines. These results suggest that 
taxol enhances the production of cytokines that are critical 
for cell-mediated and innate immunity.
Taxol increases Bcl-xL expression, an anti-apoptotic 
protein in DCs
  Western blot analysis showed that Bcl-xL expression in Taxol effect on dendritic cell viability    101
Fig. 2. Increased cytokine production in TaxolDCs. The supernatants of DCs were harvested from culture and used for enzyme-linked
immunosorbent assay. Representative data from three independent experiments are presented. Asterisk (***) indicates p ＜ 0.001 in the 
comparison of medium alone vs taxol.
Fig. 1. Dendritic cell (DC) viability is enhanced by taxol treatment. DCs were cultured in the presence of medium alone or 5 μg/ml taxol
for 3 days, and viable DCs were gated by cell-sized based flow cytometric analysis. The representative dot plots are presented (A), and
the percentage of region R1 indicates viable DCs. Statistical analysis was performed using the data from four independent experiments
(B). Asterisk (*) indicates p ＜ 0.05 in the comparison of the medium alone-treated DCs (ContDCs) vs taxol-treated DCs (TaxolDCs).
TaxolDCs was increased after 6 h of treatment, whereas the 
expression levels of Bcl-2 and Bax were not increased (Fig. 
3). The protein expression levels were calculated in 
comparison to the level of β-actin (internal control). The 
results suggest that taxol enhances DC viability via the 
increase of the anti-apoptotic protein Bcl-xL as a potential 
mechanism of action.
NF-κB signaling in taxol-induced DC survival
  Using confocal microscopy, the mobilization of NF-κB 
p65 subunit molecules from the cytosol to the nucleus were 
much greater in TaxolDCs in comparison to ContDCs (Fig. 
4A). Furthermore, TPCK, which is an inhibitor of the NF-
κB pathway, significantly decreased the viability of 
TaxolDCs, but not that of ContDCs (Fig. 4B). These results 
suggest that taxol sustains DC survival via the NF-κB 
pathway.
Discussion
  Our previous study demonstrated that taxol induces the 
altered maturation of DCs and increased their viability in 
comparison to the medium alone [6]. However, the 
mechanisms by which taxol enhances DC survival have 
not been elucidated. The present study confirmed taxol’s 
enhancement of DC viability using different assays than 
those used in the previous study. Taxol-treated DCs 
appeared as active effector cells, producing major 
cytokines involved in immune responses. Importantly, 
taxol increased the expression of the anti-apoptotic protein 
Bcl-xL, and increased the mobilization of p65 subunit 
molecules into the DC nucleus. Furthermore, we found that 
the inhibition of NF-κB by TPCK decreased DC viability.
  The Bcl-2 family proteins have been known to act as 
apoptosis-related proteins in immune cells including DCs 102    Mi-Hyoung Kim et al.
Fig. 4. NF-κB involvement in the taxol-induced effects on dendritic cells (DCs). The mobilization of NF-κB p65 molecules in DCs was
detected by staining with an anti-NF-κB p65 antibody and confocal microscopy. Arrows indicate the nuclei of DCs (A). In the inhibitor
assay, the percentage of viable DCs was measured as described in Fig. 1 (B). Asterisk (*) and sharp (#) indicate p ＜ 0.05 in the 
comparison of ContDCs vs TaxolDCs, TaxolDCs vs TaxolDCs + N-p-tosyl-L-phenylalanine chloromethyl ketone (TPCK), respectively.
Representative data from three independent experiments are presented.
Fig. 3. Bcl-xL expression in dendritic cells increased after taxol treatment. Representative data from three independent experiments are
presented (A). The optical density of each band was divided by that of the β-actin band, and the ratio at 0 h was set at 100% (B).
[5,15,16]. Among these proteins, Bcl-2 and Bcl-xL show 
anti-apoptotic activity, whereas Bax has pro-apoptotic 
activity. The present study demonstrated that the expression 
of Bcl-xL increased in DCs at early time-points of taxol 
treatment, whereas that of Bcl-2 was not increased. In a 
previous study, transduced Bcl-xL in DCs showed anti- 
apoptotic activity in a mouse tumor model [18]. Therefore, 
it seems likely that Bcl-xL was at least partially responsible 
for enhancing DC viability. As a future study, the knockdown 
study of Bcl-xL using siRNA may further confirm their role 
of taxol-treated DCs. Although the expression of Bax was 
increased in TaxolDCs, the expression of Bax occurred later 
than that of Bcl-xL, which implies that the pro-apoptotic 
effects of Bax might be minimized in the DCs during the 
treatment of taxol, 48 h.
  NF-κB is closely involved in the survival and maturation 
of DCs [11,17,20]. To investigate further the mechanisms 
of taxol-induced changes, the viablity of TPCK, an inhibitor 
of the serine protease that inhibit NF-κB signaling pathway 
in cells [20], pretreated DCs were measured. It was observed 
that TPCK significantly decreased the viability of TaxolDCs, 
but not that of ContDCs (p ＜ 0.05). In our previous study, 
the optimal concentration of TPCK (4 μM) that could inhibit 
NF-κB signaling pathways without affecting the survival 
of ContDCs was determined [9]. These results suggest that 
NF-κB is involved in the survival of TaxolDCs.
    Immunotherapy using DCs alone can provide cancer 
patients with strong benefits, including the eradication of Taxol effect on dendritic cell viability    103
cancer cells located in difficult sites to be reached via 
anti-tumor immunity [13]. However, the lack of tumor- 
specific antigens may hamper the development of a 
complete cure for cancers, although DCs have a strong 
ability to generate antigen-specific cytotoxic T lymphocytes 
[1]. Thus, recent experimental approaches to immunotherapy 
have focused on the application of DCs in combination 
with chemotherapy, specifically taxol [3,23]. This study 
has demonstrated that a popular anticancer drug, taxol, 
enhances DC viability. These findings provide a basic 
rationale for the use of taxol in DC immunotherapy and 
insights into the development of combinational DC 
therapies with other anticancer drugs that do not harm the 
viability or activity of DCs.
Acknowledgments
    This work was supported by the Korea Research 
Foundation Grant funded by the Korean Government 
(MOEHRD; KRF-2004-202-E00184) and performed 
under the program of the Basic Atomic Energy Research 
Institute (BAERI), which is a part of the Nuclear R&D 
Programs funded by the Ministry of Science & Technology 
(MOST) of Korea.
References
1. Banchereau  J,  Steinman  RM.  Dendritic  cells  and  the 
control of immunity. Nature 1998, 392, 245-252.
2. Blanco  P,  Palucka  AK,  Pascual  V,  Banchereau  J. 
Dendritic cells and cytokines in human inflammatory and 
autoimmune diseases. Cytokine Growth Factor Rev 2008, 
19, 41-52.
3. Choi GS, Lee MH, Kim SK, Kim CS, Lee HS, Im MW, 
Kil HY, Seong DH, Lee JR, Kim WC, Lee MG, Song SU. 
Combined treatment of an intratumoral injection of dendritic 
cells and systemic chemotherapy (Paclitaxel) for murine 
fibrosarcoma. Yonsei Med J 2005, 46, 835-842.
4. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK. 
Lung  Cancer  Disease  Site  Group  of  Cancer  Care 
Ontario’s Program in Evidence-based Care. Taxanes as 
first-line therapy for advanced non-small cell lung cancer: a 
systemic review and practice guideline. Lung Cancer 2005, 
50, 355-374.
5. Hou WS, Van Parijs L. A Bcl-2-dependent molecular timer 
regulates the lifespan and immunogenicity of dendritic cells. 
Nat Immunol 2004, 5, 583-589.
6. Joo HG. Altered maturation of dendritic cells by taxol, an 
anticancer drug. J Vet Sci 2003, 4, 229-234.
7. Joo HG, Goedegebuure PS, Sadanaga N, Nagoshi M, von 
Bernstorff W, Eberlein TJ. Expression and function of 
galectin-3, a β-galactoside-binding protein in activated T 
lymphocytes. J Leukoc Biol 2001, 69, 555-564.
8. Kim HJ, Kim MH, Byon YY, Park JW, Jee Y, Joo HG. 
Radioprotective effects of an acidic polysaccharide of Panax 
ginseng on bone marrow cells. J Vet Sci 2007, 8, 39-44.
9. Kim MH, Joo HG. Immunostimulatory effects of fucoidan 
on bone marrow-derived dendritic cells. Immunol Lett 2008, 
115, 138-143.
10. Kim YM, Paik SG. Induction of expression of inducible 
nitric oxide synthase by Taxol in murine macrophage cells. 
Biochem Biophys Res Commun 2005, 326, 410-416.
11. Kriehuber  E,  Bauer  W,  Charbonnier  AS,  Winter  D, 
Amatschek S, Tamandl D, Schweifer N, Stingl G, Maurer 
D. Balance between NF-κB and JNK/AP-1 activity controls 
dendritic cell life and death. Blood 2005, 106, 175-183.
12. Kubo  M,  Morisaki  T,  Matsumoto  K,  Tasaki  A, 
Yamanaka N, Nakashima H, Kuroki H, Nakamura K, 
Nakamura M, Katano M. Paclitaxel probably enhances 
cytotoxicity of natural killer cells against breast carcinoma 
cells by increasing perforin production. Cancer Immunol 
Immunother 2005, 54, 468-476.
13. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen 
TJ,  Giovannone  AJ,  Lin  JW,  Chute  DJ, Mischel  PS, 
Cloughesy TF, Roth MD. Dendritic cell vaccination in 
glioblastoma  patients  induces  systemic  and  intracranial 
T-cell responses modulated  by the local central nervous 
system tumor microenvironment. Clin Cancer Res 2005, 11, 
5515-5525.
14. Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances 
macrophage  IL-12  production  in  tumor-bearing  hosts 
through nitric oxide. J Immunol 1999, 162, 6811-6818.
15. Nopora  A,  Brocker  T.  Bcl-2  controls  dendritic  cell 
longevity in vivo. J Immunol 2002, 169, 3006-3014.
16. Opferman  JT,  Korsmeyer  SJ.  Apoptosis  in  the 
development and maintenance of the immune system. Nat 
Immunol 2003, 4, 410-415.
17. Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA. Dendritic 
cell  development  and  survival  require  distinct  NF-κB 
subunits. Immunity 2002, 16, 257-270.
18. Pirtskhalaishvili G, Shurin GV, Gambotto A, Esche C, 
Wahl M, Yurkovetsky ZR, Robbins PD, Shurin MR. 
Transduction of dendritic cells with Bcl-xL increases their 
resistance  to  prostate  cancer-induced  apoptosis  and 
antitumor effect in mice. J Immunol 2000, 165, 1956-1964.
19. Rang  HP,  Dale  MM,  Ritter  JM,  Moore  PK. 
Pharmacology. 5th ed. pp. 696-698, Churchill Livingston, 
Kidlington, 2004.
20. Rescigno  M,  Martino  M,  Sutherland  CL,  Gold  MR, 
Ricciardi-Castagnoli  P.  Dendritic  cell  survival  and 
maturation are regulated by different signaling pathways. J 
Exp Med 1998, 188, 2175-2180.
21. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a 
novel investigational antimicrotubule agent. J Natl Cancer 
Inst 1990, 82, 1247-1259.
22. Wiseman LR, Spencer CM. Paclitaxel. An update of its use 
in the treatment of metastatic breast cancer and ovarian and 
other gynaecological cancers. Drugs Aging 1998, 12, 305- 
334.
23. Zhong H, Han B, Tourkova IL, Lokshin A, Rosenbloom 
A, Shurin MR, Shurin GV. Low-dose paclitaxel prior to 
intratumoral dendritic cell vaccine modulates intratumoral 
cytokine network and lung cancer growth. Clin Cancer Res 
2007, 13, 5455-5462.